> [!Info] Result > SYF represents one of four investments in Roundtable's Q1 2026 cohort, comprising 6.25% of the fund's 16-position portfolio for the financial year. Per the 4x4x4 methodology, this position will undergo a midpoint review in Q3 2026 and a comprehensive exit analysis upon disposition in Q1 2027. *** **Synchrony Financial (SYF)** **Date**: 31 March 2026, Q1 2026 **Adriano Giorgio** - [email protected] **Action**: Long / Aggressive Price Target: $218 (~218% return) *** # Recommendation > [!Example] The Elevator Pitch > > I recommend a long position in Synchrony Financial (SYF) with an ambitious price target of $218 (~235% return) based on DCF analysis and normalized valuation multiples. I believe that SYF's stock price does not currently reflect (a) the company's exceptional free cash flow generation ($9.85B annually on $23B market cap, representing a 42% FCF yield); (b) SYF's market-leading position in private label credit cards with deep retail partnerships across health & wellness (including expanding CareCredit ecosystem with 1.2M+ pet insurance policyholders), home, auto, and specialty retail; and (c) the company's proven ability to generate superior returns (23% profit margins, 2.9% ROA) through an asset-light business model that requires minimal capital expenditure, trading at an extreme discount to intrinsic value (7x P/E, 2.5x P/FCF vs. consensus analyst target of $86.42). *** # Business Description ## SYF History > [!Quote] SYF Summary pulled from Yahoo Finance > Synchrony Financial, together with its subsidiaries, operates as a consumer financial services company in the United States. The company provides credit products, such as credit cards, commercial credit products, and consumer installment loans. It also offers private label credit cards, dual and general purpose co-branded cards, short- and long-term installment loans, and consumer banking products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts, savings accounts, and sweep and affinity deposits, as well as accepts deposits through third-party firms. In addition, the company provides debt cancellation products to its credit card customers through online and mobile channels; and healthcare payments and financing solutions under the CareCredit and Walgreens brands; payments and financing solutions in the apparel, specialty retail, outdoor, music, and luxury industries, such as American Eagle, Dick's Sporting Goods, Guitar Center, Pandora, Polaris, Suzuki, and Sweetwater. It offers its credit products through programs established with a group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations, and healthcare service providers; and deposit products through various channels, such as digital and print. It serves digital, health and wellness, retail, home, auto, telecommunications, pet, outdoor, and other industries. The company was founded in 1932 and is headquartered in Stamford, Connecticut. **Sector:** Financial Services **Industry:** Credit Services ## Management & Governance | Name | Title | | ------------------- | ------------------------------ | | Brian D. Doubles | President, CEO & Director | | Brian J. Wenzel Sr. | EVP & CFO | | Carol D. Juel | EVP & Chief Technology Officer | | Jonathan S. Mothner | EVP & Chief Risk/Legal Officer | | Alberto Casellas | EVP & CEO Health & Wellness | | D.J. Casto | EVP & Chief Human Resources | | Bart Schaller | EVP & CEO Digital | | Michael Bopp | EVP & Chief Growth Officer | - Key Observations - Experienced leadership via CEO Brian Doubles who joined in 2014 (7+ years tenure) - Specialized org structure through dedicated C-suite roles for Health & Wellness, Digital, Growth (Signals strategic priorities) Synchrony Financial’s ISS governance quality score as of 1 March 2026 is 3. The pillar scores are audited: 3; board: 4; shareholder rights: 5; compensation: 2. Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk. ## Ownership & Insider Activity **Institutional & Insider Ownership:** - **Institutional Ownership:** 96.48% (extremely high conviction) - **Insider Ownership:** 0.33% (minimal but typical for large financial) **Major Institutional Holders:** 1. State Street Corp: 19,080,903 shares ($1.36B) 2. Bank of America Corp: 14,335,213 shares ($1.02B) 3. Ameriprise Financial: 5,307,077 shares ($354M) 4. Nordea Investment Management: 5,134,903 shares ($432M) 5. Norges Bank: New position ($299M) **Recent Insider Activity (Last 3 Months):** - **Total Insider Sales:** 379,928 shares ($26.17M) - **Notable Sales:** - Alberto Casellas (EVP Health & Wellness): 14,399 shares @ $67.71 (-22.24% position) - Brian J. Wenzel Sr. (CFO): 47,112 shares @ $67.16 (-42.32% position) **Institutional Activity Q4 2025:** - **Assenagon Asset Management:** Reduced position 89.4% (sold 434,737 shares) - **State Street:** Increased 1.0% (+191,920 shares) - **Bank of America:** Increased 5.4% (+739,832 shares) - **Ameriprise:** Increased 8.3% (+406,796 shares) - **Nordea:** Increased 13.0% (+592,567 shares) **Interpretation:** Mixed signals - significant insider selling at $67-68 (13% above current price) suggests executives thought stock was fairly valued. However, major institutions (State Street, BofA, Ameriprise, Nordea) continued accumulating, showing confidence despite insider sales. *** # Financials ## Trading and Operating Statistics | Metric | Value | | -------------------- | ------------------------------- | | **Current Price** | $65.31 | | **Market Cap** | $23B | | **Enterprise Value** | $37.81B | | **P/E (TTM)** | 7.03x | | **Forward P/E** | 7.09x | | **EPS (TTM)** | $9.28 | | **Q4 2025 EPS** | $2.18 (beat est. $2.02 by 7.9%) | | **FY2026 Guidance** | $9.10-9.50 EPS | | **P/FCF** | 2.47x | | **PEG Ratio** | 0.58 | | **P/B** | 1.46x | | **Dividend Yield** | 1.84% ($1.20 annual) | | **52-Week Range** | $40.54 - $88.77 | | **Beta** | 1.42 | | **Debt-to-Equity** | 0.98 | **Recent Performance:** - **1-Year:** +26.93% - **3-Months:** -22.87% (sector rotation, credit concerns) - **1-Month:** +5.43% - **50-Day MA:** $70.73 - **200-Day MA:** $74.89 ## Financial Performance **FCF History & Projections (All numbers in millions):** | Year | FCF | YoY Growth | Notes | | | --------- | ------- | ---------- | -------------------- | --- | | **2022** | $6,694 | - | - | | | **2023** | $8,593 | +28.4% | Strong expansion | | | **2024** | $9,848 | +14.6% | Growth decelerating | | | **2025** | $9,851 | +0.03% | Stalled growth | | | **2026E** | $10,147 | +3.0% | Base case projection | | | **2030E** | $11,420 | +3.0% CAGR | Conservative growth | | **Key Observations:** - **FCF Margin:** 65.7% (exceptional cash conversion) - **Historical 3-Year CAGR:** 14.0% - **Projected 5-Year CAGR:** 3.0% (conservative given stagnation) ![[Screenshot 2026-03-30 at 1.27.22 PM.png|634]] SYF vs Russell 1000 (Indexed Performance, 2022–Present) ## Peer Comparison | **Metric** | **SYF** | **ALLY** | **COF** | **BFH** | **SYF vs. Avg** | | -------------------- | ------- | -------- | ------- | ------- | --------------------------- | | **P/E** | 7.1x | 16.2x | 54.0x | 6.8x | **Attractive (2nd lowest)** | | **Price / FCF** | 2.5x | 18.4x | 3.8x | 1.7x | **Best-in-class (ex-BFH)** | | **Operating Margin** | 26.9% | 26.1% | 20.2% | 28.6% | **Top tier** | | **Profit Margin** | 23.2% | 8.5% | 4.1% | 13.5% | **Best** | | **ROA** | 2.9% | 0.4% | 0.4% | 2.3% | **Best** | | **1Y Price Return** | 22.9% | 4.6% | 0.2% | 42.7% | **Strong (2nd best)** | Synchrony Financial shows higher profitability than peers with leading profit margin and ROA, supported by consistently strong operating margins. It also trades at a low valuation of around 7x earnings while outperforming major peers like Capital One and Ally over the past year. ## DCF Valuation Summary **Model Inputs & Assumptions:** | Parameter | Value | Justification | | ---------------------------- | ----------------- | ------------------------------------ | | **Growth Rate** | 3.0% (Years 1-10) | Conservative given 0% current growth | | **Terminal Growth** | 2.5% | In line with GDP | | **Risk-Free Rate** | 4.16% | 10-Year Treasury | | **Beta** | 1.41 | From Yahoo Finance | | **Equity Risk Premium** | 5.50% | Standard US equity premium | | **Cost of Equity** | 11.91% | CAPM calculation | | **Cost of Debt (Pre-Tax)** | 27.24% | Likely overstated | | **Cost of Debt (After-Tax)** | 20.94% | 23.13% tax rate | | **Equity Weight** | 59.85% | Market value based | | **Debt Weight** | 40.15% | Market value based | | **WACC** | 15.54% | Weighted average | **DCF Output:** | Component | Value | | ---------------------------------- | ----------- | | **PV of Explicit FCF (2026-2035)** | $52.15B | | **Terminal Value (PV)** | $23.85B | | **Total Enterprise Value** | $75.99B | | **+ Cash & Equivalents** | $14.97B | | **- Total Debt** | $15.18B | | **= Equity Value** | $75.79B | | **÷ Shares Outstanding** | 347.6M | | **= DCF Fair Value** | **$218.03** | | | | | **Current Price** | $65.31 | | **Implied Upside** | **+234%** | See full DCF Analysis [here](https://docs.google.com/spreadsheets/d/1YcSERNklTahGEopOhCreInNYexhCv9x-SSkri3Nvy1I/edit?usp=sharing) ## Sensitivity Analysis ![[Screenshot 2026-03-30 at 1.34.31 PM.png|697]] **Key Observations:** - Even at conservative WACC (10-11%) and terminal growth (2-2.5%), fair value is $326-380 - Base case (WACC 15.54%, Terminal 2.5%) = $218 - Sensitivity table shows massive upside across all reasonable assumptions - Market pricing implies WACC >20% or terminal growth <1% (economic decline scenario) ## Consensus Analyst Estimates **Analyst Ratings (21 analysts):** - **Strong Buy:** 1 - **Buy:** 13 - **Hold:** 7 - **Sell:** 0 - **Consensus:** "Moderate Buy" **Price Targets:** - **Consensus Target:** $86.42 (+32.3% upside) - **High Target:** $98.00 (Keefe Bruyette) - **Low Target:** $83.00 (Robert W. Baird) - **Simply Wall St Fair Value:** $105.00 (+60.7% upside, 37.8% undervalued) - **Our DCF Fair Value:** $218.03 (+234% upside) **Recent Analyst Actions:** - **Wolfe Research:** Initiated "Outperform" @ $92 (Dec 8) - **Keefe Bruyette:** Raised to $98 "Outperform" (Jan 2) - **Royal Bank of Canada:** Lowered $91 → $85 "Sector Perform" (Jan 28) - **Robert W. Baird:** Upgraded Neutral → Outperform @ $83 (Feb 13) - **BTIG Research:** Reiterated "Buy" @ $96 (Mar 11) **Analyst Revenue & Earnings Projections:** - **2026E EPS:** $9.10-9.50 (management guidance) - **2027E EPS:** $7.67 (consensus) - **2028E Revenue:** $16.5B (+21.7% CAGR from 2025) - **2028E Earnings:** $3.3B (vs. $3.2B current) *** # Competitive Advantages ## Industry Verticals & Strategic Partnerships 1. Health & Wellness (largest and fastest growing) - **Large and growing platform:** 60,000+ providers, 13M active accounts, covering dental, vision, veterinary, cosmetic, and other healthcare services - **Strong partner ecosystem:** Includes Walgreens and multiple pet insurers, with the recent Figo partnership adding 1.2M+ policyholders - **New functionality (March 2026):** Enables upfront vet payments with automatic insurance reimbursements, removing out-of-pocket delays - **Compelling tailwinds:** Driven by aging demographics, strong pet industry growth, and more resilient healthcare spending, while expanding its embedded payments ecosystem 2. Retail & E-Commerce - **Partners with the following major firms**: Amazon, American Eagle Outfitters, Dick's Sporting Goods, TJX Companies (TJ Maxx, Marshalls), Lowe's, Gap Inc., Guitar Center, Pandora, and Sweetwater 3. Auto & Outdoor - **Partners with the following major firms**: Polaris, Suzuki, Yamaha, various specialized outdoor retailers 4. Other Verticals - **Telecommunications** - Device financing - **Luxury Goods** - High-ticket purchases - **Furniture & Home** - Room & Board, Ashley Furniture - **Electronics** - Sony, JBL As a result, purely from strategic partnerships SYF can extract the following value ..... -> 1. Partnership lock-in bodes well for future due to high switching costs, and SYF's integration in partner operations - Long-term exclusive agreements typically last 5-10 years (e.g. American Eagle has used SYF for 20+ years) - SYF embedded in partner checkout flows (Online and/or in-store) - High partner switching costs (IT integration, customer disruption during transition, loss of customer data/insights, regulatory compliance re-approval aka headache zone) 2. SYF can leverage CareCredit's expansive network (Positive network effects) - 60k+ provider network (Largest in healthcare financing) - Patient seek providers that accept Carecredit, and providers join because patients demand it aka a self-reinforcing flywheel - More providers -> More patients -> more providers 3. Partnering with various sectors allows for attractive industry-specific credit models with 90+ years of consumer credit history 4. The finance of it all works out. SYF employs minimal Capex requirements (<50M annually), has an extremely high FCF conversion for financial services (~65%), and is dropping $14.98B revenue to be the number 1 private label credit. *** # Risk Overview ## Risks Ranked by Impact x Probability 1. Revenue Stagnation - High probability, with a decent impact as SYF is already priced in at 7x P/E - The mitigants? 1. CareCredit is growing (Ageing demographics and pet boom) 2. The new Figo partnership is adding 1.2M policy holders 3. Their existing partnerships with major companies like Amazon are stable, helping at least support their revenue 2. Credit Cycle deteriorates - Decent probability, and would have a significant impact as it could compress margins 200-300 bps - Mitigants 1. CareCredit has lower default rates (around 3% vs 5-7% industry averages) 2. Specialized in underwriting by vertical 3. Already trading at 7x P/E (Meaning the bad credit scenario is already priced in) 4. Net margin still ~16% meaning room for compression and still be profitable 3. Partner concentration - Lower probability but would have a big impact if a major partner (Amazon, Walmart, Lowe's) exits - Mitigants 1. SYF has 20+ major partners across industries 2. Long-term contracts and high switching costs for partners 3. CareCredit is its own ecosystem (60k providers = diversification) 4. Regulatory Headwinds - A fair probability and impact as fee restrictions could reduce revenue 5-10% - Mitigants include 1. Already a heavily regulated sector (Unlike AI or the sort, and compliance infrastructure at SYF already exists) 2. Would be an industry-wide issue affecting competitors 3. SYF could adjust pricing/underwriting to offset 5. Insider selling signal - Probability N/A as this has already occurred - CFO and Health & Wellness CEO sold at $67-68 with 42% and 22% ownership respectively - A Breakdown - Concern - Executives thought $67-68 was a fair value - Counter point - They still own material positions, option exercises which show long-term belief in SYF's growth *** # Investment Recommendation Our 4 reasons, as per the 4x4x4 Methodology : 1. SYF is significantly mis-priced, with conservative re-rating scenarios still showing massive upside, partnership ecosystem expanding, and a sound business that is still generating ~10B in annual FCF 2. SYF offers best-in-class profitability, is a cash generation machine, and with a durable competitive moat via their strategic partnerships showcases their "Financial fortress"-ness 3. SYF's recent strategic catalyst to partner with Figo Pet Insurance adds 1.2M+ policyholders into their already massive CareCredit ecosystem, showing their ability to grow even without core retail recovery 4. Risks are manageable (See risks section) > [!Example] Thesis > SYF is a hidden FCF machine with a defensible moat (CareCredit network, retail partnerships) trading at distressed multiples because the market confuses cyclical revenue stagnation with permanent structural decline. The recent Figo partnership proves the ecosystem is expanding, not contracting. At 7x P/E generating $9.85B annual FCF, any stabilization in revenue or credit metrics triggers re-rating to 10-12x P/E, delivering 50-100%+ returns. *** # Resources - [DCF Analysis Page for SYF](https://docs.google.com/spreadsheets/d/1YcSERNklTahGEopOhCreInNYexhCv9x-SSkri3Nvy1I/edit?usp=sharing) - [SYF Yahoo Finance Page](https://uk.finance.yahoo.com/quote/SYF/) - [SYF Investor Page](https://investors.synchrony.com/)